Search research articles
Contact Us
Filters
Showing results (241-250 of 319) with videos related to
Page
of 32
Sort By:
Biorxiv : the Preprint Server for Biology
|
March 30, 2023
Self-delivering CRISPR RNAs for AAV Co-delivery and Genome Editing <i>in vivo</i>
Han Zhang, Karen Kelly, Jonathan Lee, et al.
BMJ Open
|
December 12, 2018
Open randomised trial of the (Arabin) pessary to prevent preterm birth in twin pregnancy with health economics and acceptability: STOPPIT-2-a study protocol
Jane E Norman, John Norrie, Graeme Maclennan, et al.
Infectious Diseases and Therapy
|
September 12, 2023
Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
Louise Murdoch, Karen Quan, James A Baber, et al.
Trials
|
March 21, 2026
PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trial
Diana Johnson, Ruth Thomas, Seonaidh Cotton, et al.
Vaccines
|
April 27, 2026
A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18-64 Years of Age (Preliminary Results)
Rucha Dadhe, Juleen Gayed, Muneeb Iqbal, et al.
Nucleic Acids Research
|
November 30, 2023
Self-delivering, chemically modified CRISPR RNAs for AAV co-delivery and genome editing in vivo
Han Zhang, Karen Kelly, Jonathan Lee, et al.
The New England Journal of Medicine
|
January 18, 2013
Short-course antiretroviral therapy in primary HIV infection
, Sarah Fidler, Kholoud Porter, et al.
Vaccines
|
February 26, 2025
Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
Joel M Neutel, Rahsan Erdem, Qin Jiang, et al.
Elife
|
September 14, 2014
HIV-1 DNA predicts disease progression and post-treatment virological control
James P Williams, Jacob Hurst, Wolfgang Stöhr, et al.
AIDS (London, England)
|
April 2, 2005
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine
Ana Barrios, Ana Rendón, Eugenia Negredo, et al.
Page
of 32
Search research articles
Search
Showing results (241-250 of 319) with videos related to
Sort By:
Page
of 32
Biorxiv : the Preprint Server for Biology
|
March 30, 2023
Self-delivering CRISPR RNAs for AAV Co-delivery and Genome Editing <i>in vivo</i>
Han Zhang, Karen Kelly, Jonathan Lee, et al.
BMJ Open
|
December 12, 2018
Open randomised trial of the (Arabin) pessary to prevent preterm birth in twin pregnancy with health economics and acceptability: STOPPIT-2-a study protocol
Jane E Norman, John Norrie, Graeme Maclennan, et al.
Infectious Diseases and Therapy
|
September 12, 2023
Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
Louise Murdoch, Karen Quan, James A Baber, et al.
Trials
|
March 21, 2026
PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trial
Diana Johnson, Ruth Thomas, Seonaidh Cotton, et al.
Vaccines
|
April 27, 2026
A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18-64 Years of Age (Preliminary Results)
Rucha Dadhe, Juleen Gayed, Muneeb Iqbal, et al.
Nucleic Acids Research
|
November 30, 2023
Self-delivering, chemically modified CRISPR RNAs for AAV co-delivery and genome editing in vivo
Han Zhang, Karen Kelly, Jonathan Lee, et al.
The New England Journal of Medicine
|
January 18, 2013
Short-course antiretroviral therapy in primary HIV infection
, Sarah Fidler, Kholoud Porter, et al.
Vaccines
|
February 26, 2025
Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
Joel M Neutel, Rahsan Erdem, Qin Jiang, et al.
Elife
|
September 14, 2014
HIV-1 DNA predicts disease progression and post-treatment virological control
James P Williams, Jacob Hurst, Wolfgang Stöhr, et al.
AIDS (London, England)
|
April 2, 2005
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine
Ana Barrios, Ana Rendón, Eugenia Negredo, et al.
Page
of 32